CoChat

Inhibition of DYRK1A Stimulates Human β-Cell Proliferation

Open access
Dirice, Ercument, Walpita, Deepika, Vetere, Amedeo, Meier, Bennett C., Kahraman, Sevim, Hu, Jiang, Dančík, Vlado, Burns, Sean M., Gilbert, Tamara J., Olson, David E., Clemons, Paul A., Kulkarni, Rohit N., Wagner, Bridget K. · 2016 · Diabetes
Cited by 209

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Restoring functional β-cell mass is an important therapeutic goal for both type 1 and type 2 diabetes (1). While proliferation of existing β-cells is the primary means of β-cell replacement in rodents (2), it is unclear whether a similar principle applies to humans, as human β-cells are remarkably resistant to stimulation of division (3,4). Here, we show that 5-iodotubercidin (5-IT), an annotated adenosine kinase inhibitor previously reported to increase proliferation in rodent and porcine islets (5), strongly and selectively increases human β-cell proliferation in vitro and in vivo. Remarkably, 5-IT also increased glucose-dependent insulin secretion after prolonged treatment. Kinome profiling revealed 5-IT to be a potent and selective inhibitor of the dual-specificity tyrosine phosphorylation–regulated kinase (DYRK) and cell division cycle–like kinase families. Induction of β-cell proliferation by either 5-IT or harmine, another natural product DYRK1A inhibitor, was suppressed by coincubation with the calcineurin inhibitor FK506, suggesting involvement of DYRK1A and nuclear factor of activated T cells signaling. Gene expression profiling in whole islets treated with 5-IT revealed induction of proliferation- and cell cycle–related genes, suggesting that true proliferation is induced by 5-IT. Furthermore, 5-IT promotes β-cell proliferation in human islets grafted under the kidney capsule of NOD-scid IL2Rgnull mice. These results point to inhibition of DYRK1A as a therapeutic strategy to increase human β-cell proliferation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db15-1127

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 209

Metadata

Authors
Dirice, E., Walpita, D., Vetere, A., Meier, B. C., Kahraman, S., Hu, J., Dančík, V., Burns, S. M., Gilbert, T. J., Olson, D. E., Clemons, P. A., Kulkarni, R. N., & Wagner, B. K.
Venue
Diabetes
Published
2016-03-07
Volume
65
Issue
6
Pages
1660-1671
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2322477027
Cited by
209
References
8
FWCI
18.59
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibition of DYRK1A Stimulates Human β-Cell Proliferation. https://app.cochat.ai/papers/10.2337/db15-1127
The paper
Dirice, E., Walpita, D., Vetere, A., Meier, B. C., Kahraman, S., Hu, J., Dančík, V., Burns, S. M., Gilbert, T. J., Olson, D. E., Clemons, P. A., Kulkarni, R. N., & Wagner, B. K. (2016). Inhibition of DYRK1A Stimulates Human β-Cell Proliferation. Diabetes. https://doi.org/10.2337/db15-1127

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.